AN INTERNATIONAL OBSERVATIONAL STUDY TO ASSESS THE USE OF SORAFENIB AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): OPTIMIS

被引：1
|
作者：
Peck-Radosavljevic, M. [1 ]
Raoul, J. -L. [2 ]
Lee, H. C. [3 ]
Kudo, M. [4 ]
Nakajima, K. [5 ]
Cheng, A. -L. [6 ]
机构：
[1] Inst J Paoli I Calmettes, F-13009 Marseille, France
[2] Med Univ Vienna, Vienna, Austria
[3] Asan Med Ctr, Seoul, South Korea
[4] Kinki Univ, Sch Med, Osaka 589, Japan
[5] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31517-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1338
引用
收藏
页码：S858 / S858
页数：1
相关论文
共 50 条
  • [1] OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
    Peck-Radosavijevic, Markus
    Raoul, Jean-Luc
    Lee, Han Chu
    Kudo, Masatoshi
    Nakajima, Keiko
    Chong, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS - An international observational study assessing the use of sorafenib after TACE
    Peck-Radosavljevic, M.
    Raoul, J-L
    Lee, H. C.
    Cheng, A-L
    Nakajima, K.
    Kudo, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 282 - 282
  • [3] Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS-An international observational study assessing the use of sorafenib after TACE.
    Kudo, Masatoshi
    Raoul, Jean-Luc
    Lee, Han Chu
    Cheng, Ann-Lii
    Nakajima, Keiko
    Peck-Radosavljevic, Markus
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Outcomes of Patients (pts) with Hepatocellular Carcinoma (HCC) Treated with Transarterial Chemoembolization (TACE): Global OPTIMIS Final Analysis
    Peck-Radosavljevic, Markus
    Kudo, Masatoshi
    Raoul, Jean-Luc
    Lee, Han Chu
    Decaens, Thomas
    Heo, Jeong
    Lin, Shi-Ming
    Shan, Hong
    Yang, Yefa
    Bayh, Inga
    Nakajima, Keiko
    Cheng, Ann-Lii
    HEPATOLOGY, 2018, 68 : 167A - 168A
  • [5] Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis.
    Peck-Radosavljevic, Markus
    Kudo, Masatoshi
    Raoul, Jean-Luc
    Lee, Han Chu
    Decaens, Thomas
    Heo, Jeong
    Lin, Shi-Ming
    Shan, Hong
    Yang, Yefa
    Bayh, Inga
    Nakajima, Keiko
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] FACTORS AFFECTING OUTCOMES AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) FOR HEPATOCELLULAR CARCINOMA (HCC)
    Suman, A.
    Sharma, A.
    Venkataperumal, S.
    Limaye, A.
    Morelli, G.
    Clark, V.
    Soldevila-Pico, C.
    Cabrera, R.
    Firpi, R.
    Nelson, D.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S395 - S395
  • [7] Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada
    Raoul, J-L.
    Decaens, T.
    Burak, K.
    Koskinas, J.
    Villadsen, G. E.
    Heurgue-Berlot, A.
    Bayh, I.
    Cheng, A-L.
    Kudo, M.
    Lee, H. C.
    Nakajima, K.
    Peck-Radosavljevic, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 240 - 240
  • [8] Characteristics of Hepatocellular Carcinoma (HCC) Patients Who Received Transarterial Chemoembolization ( TACE) Prior to Sorafenib: US GIDEON Experience
    Geschwind, Jean-Francois H.
    Cohn, Allen
    El-Khoueiry, Anthony
    Gholam, Pierre M.
    Goldenberg, Alec
    Mantry, Parvez S.
    Martin, Robert
    McGuire, Brendan M.
    Miksad, Rebecca A.
    Piperdi, Bilal
    Sanyal, Arun J.
    Venook, Alan
    Germino, Joseph F.
    Marrero, Jorge A.
    HEPATOLOGY, 2013, 58 : 1236A - 1237A
  • [9] Predictors of poor outcome for transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).
    Prins, Petra
    Singh, Bhavana P.
    Armstrong, Samantha Ann
    He, Aiwu Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Thalidomide (Thal) tolerance in patients treated with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)
    Goldenberg, A
    Volm, M
    Hochster, H
    Muggia, F
    Rosen, R
    Teperman, L
    Morgan, G
    Schwartz, J
    Sung, M
    Wadler, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 376S - 376S
12345